Structural imaging remains an essential component of diagnosis, staging and response
assessment in patients with cancer; however, as clinicians increasingly seek to …

Despite strong evidence of effectiveness, colorectal cancer (CRC) screening remains
underused. Currently, there are several options for CRC screening, each with its own …

Cancer development is driven by the accumulation of alterations affecting the structure and
function of the genome. Whereas genetic changes disrupt the DNA sequence, epigenetic …

Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …

Summary In the Circulating Cell-free Genome Atlas (NCT02889978) substudy 1, we
evaluate several approaches for a circulating cell-free DNA (cfDNA)-based multi-cancer …

Pancreatic ductal adenocarcinoma (PDAC), the most deadly solid malignancy, is typically
detected late and at an inoperable stage. Early or incidental detection is associated with …

Hepatocellular carcinoma (HCC) mortality rates are increasing globally, and particularly in
the Western world. Cirrhosis remains the predominant risk factor for HCC. However …

Cancer is a worldwide pandemic. The burden it imposes grows steadily on a global scale
causing emotional, physical, and financial strains on individuals, families, and health care …

DNA methylation data have become a valuable source of information for biomarker
development, because, unlike static genetic risk estimates, DNA methylation varies …

Effective screening modalities are currently available for only a small subset of cancers, and
they generally have suboptimal performance with complicated procedures. Therefore, there …